CRISPR Therapeutics’ (CRSP) “Buy” Rating Reiterated at HC Wainwright

HC Wainwright restated their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP) in a research report sent to investors on Thursday,Benzinga reports. They currently have a $65.00 price target on the stock.

Other research analysts also recently issued research reports about the stock. TD Cowen raised shares of CRISPR Therapeutics from a “sell” rating to a “hold” rating and set a $35.00 target price for the company in a research note on Wednesday. Barclays boosted their price objective on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the company an “equal weight” rating in a research report on Wednesday. Royal Bank of Canada decreased their target price on shares of CRISPR Therapeutics from $53.00 to $48.00 and set a “sector perform” rating on the stock in a research report on Wednesday. Chardan Capital reiterated a “buy” rating and issued a $94.00 price target on shares of CRISPR Therapeutics in a report on Tuesday, December 10th. Finally, StockNews.com upgraded CRISPR Therapeutics to a “sell” rating in a report on Monday, December 30th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average price target of $74.50.

CRISPR Therapeutics Price Performance

CRSP stock opened at $49.72 on Thursday. CRISPR Therapeutics has a 12 month low of $36.52 and a 12 month high of $91.10. The firm has a market capitalization of $4.24 billion, a PE ratio of -17.57 and a beta of 1.67. The company’s 50 day simple moving average is $41.89 and its 200-day simple moving average is $46.10.

CRISPR Therapeutics (NASDAQ:CRSP) last announced its earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 12.15% and a negative net margin of 118.13%. As a group, sell-side analysts anticipate that CRISPR Therapeutics will post -5.08 earnings per share for the current year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 15,000 shares of the firm’s stock in a transaction dated Monday, December 2nd. The stock was sold at an average price of $55.10, for a total transaction of $826,500.00. Following the sale, the chief executive officer now directly owns 181,540 shares in the company, valued at approximately $10,002,854. This trade represents a 7.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this link. 4.10% of the stock is currently owned by insiders.

Institutional Trading of CRISPR Therapeutics

Several large investors have recently bought and sold shares of CRSP. Northern Trust Corp lifted its holdings in CRISPR Therapeutics by 12.9% in the 4th quarter. Northern Trust Corp now owns 257,168 shares of the company’s stock worth $10,122,000 after buying an additional 29,416 shares in the last quarter. Susquehanna Fundamental Investments LLC acquired a new position in shares of CRISPR Therapeutics in the fourth quarter worth about $3,636,000. Virtus ETF Advisers LLC lifted its stake in shares of CRISPR Therapeutics by 52.6% in the fourth quarter. Virtus ETF Advisers LLC now owns 7,702 shares of the company’s stock worth $303,000 after acquiring an additional 2,655 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its stake in CRISPR Therapeutics by 39.2% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company’s stock valued at $150,029,000 after purchasing an additional 1,074,238 shares in the last quarter. Finally, Price T Rowe Associates Inc. MD grew its stake in CRISPR Therapeutics by 3.4% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 24,563 shares of the company’s stock valued at $967,000 after purchasing an additional 800 shares in the last quarter. Institutional investors and hedge funds own 69.20% of the company’s stock.

CRISPR Therapeutics Company Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.